United States: FDA Issues Its First Postmarketing Safety Reporting Regulations For Combination Products

The Food and Drug Administration (FDA) recently published a final rule setting forth the first postmarketing safety reporting regulations for combination products that have received FDA marketing authorization. Postmarketing Safety Reporting for Combination Products, 81(244) Fed. Reg. 92603-92626 (Dec. 20, 2016) (to be codified at 21 C.F.R. pt. 4) ("Final Rule"); see also 21 C.F.R. § 3.2(e) (defining "combination product" as, inter alia, a product comprised of two or more regulated components). The rule has an effective date of January 19, 2017, with some provisions requiring compliance on that date and others requiring compliance within eighteen months. Final Rule at 92603, 92619.

The new regulations are part of the FDA's ongoing effort to ensure the consistency and appropriateness of the regulatory requirements for combination products. Id. at 92603. Previously, the FDA applied postmarketing safety reporting regulations from one or more of the combination product's constituent parts. Id. at 92604. This led to inconsistent, incomplete, and duplicative reporting because the regulations for drugs, biological products, and devices differ from one another in their standards and timeframes. Id. The FDA intends the new regulations to ensure consistent, complete postmarketing safety reporting for combination products while avoiding duplicative reporting. Id. at 92604, 92606.

The new regulations do not constitute an entirely new reporting scheme for combination products, as proposed by some of the FDA's stakeholders. Id. at 92605. Instead, the regulations explain which of the existing postmarketing safety reporting regulations apply to combination product applicants (entities holding an application for a combination product) and constituent part applicants (entities holding an application for a drug, biological product, or device as a constituent part of a combination product where the other parts' applications are held by other entities). Id. at 92604; see also id. at 92624-25 (adding 21 C.F.R. §§ 4.100 and 4.101 to specify who is subject to the rule and to define certain terms).

Under the new regulations, combination product and constituent part applicants must comply with postmarketing safety reporting requirements corresponding to the type of application under which they received marketing authorization. Id. at 92604, 92605, 92607; see also id. at 92625 (adding 21 C.F.R. § 4.102(b)). Applicants who received authorization under a new drug application (NDA) or abbreviated new drug application (ANDA) must comply with the requirements described in 21 C.F.R. part 314. Id. at 92625 (adding 21 C.F.R. § 4.102(b)(2)). Applicants who received authorization under a biologics licensing application (BLA) must comply with the requirements described in 21 C.F.R. parts 600 and 606. Id. (adding 21 C.F.R. § 4.102(b)(3)). And applicants who received authorization under a premarket approval application (PMA) or other device application must comply with the requirements described in 21 C.F.R. parts 803 and 806. Id. (adding 21 C.F.R. § 4.102(b)(1)).

In addition, combination product applicants must submit specified reports based on the product's constituent parts. Id. at 92604, 92606, 92607; see also id. at 92625-26 (adding 21 C.F.R. § 4.102(c)). The FDA is requiring these reports regardless of application type because they relate to particular characteristics and safety issues associated with the type of constituent part. Id. at 92606, 92608, 92614. For example, if the combination product contains a drug, the applicant must submit field alert reports regardless of application type. Id. at 92625-26 (adding 21 C.F.R. § 4.102(c)(2)). If the product contains a biological product, the applicant must submit biological product deviation reports. Id. at 92626 (adding 21 C.F.R. § 4.102(c)(3)). If the product contains a device, the applicant must submit five-day reports and malfunction reports, id. at 92625 (adding 21 C.F.R. § 4.102(c)(1)), and must summarize and analyze these reports in any NDA, ANDA, or BLA periodic safety update reports it submits under 21 C.F.R. § 314.80 or § 600.80, id. at 92608; see also id. at 92626 (adding 21 C.F.R. § 4.102(d)(1)).

The new regulations require constituent part applicants to share with the combination product's other constituent part applicants within five days information about events involving death or serious injury and information about adverse experiences. Id. at 92604, 92608; see also id. at 92626 (adding 21 C.F.R. § 4.103(a)). The FDA reasons that this expedited sharing of information will ensure timely, complete reporting with regard to events that are brought to the attention of only one constituent part applicant. Id. at 92616. It notes that the regulations do not require the sharing of trade secret or confidential commercial information. Id. at 92617. Applicants are also not required to modify, organize, or evaluate the information before forwarding it to the other constituent part applicants. Id. Applicants must maintain records relating to the shared information, including the identity of the applicants with whom they shared the information and the date shared, for the longest retention period that applies. Id. at 92609; see also id. at 92626 (adding 21 C.F.R. §§ 4.103(b), 4.104(a)).

The regulations also specify which submission procedures and recordkeeping requirements applicants must follow. Id. at 92604, 92609; see also id. at 92626 (adding 21 C.F.R. §§ 4.104, 4.105). Constituent part applicants generally must comply with submission and recordkeeping requirements based on their application type. Id. at 92609; see also id. at 92626 (adding 21 C.F.R. §§ 4.104(a), 4.105(a)). Combination product applicants generally must comply with submission requirements based on the type of report they are submitting, and they must maintain records for the longest applicable period. Id. at 92609 (noting that both 21 C.F.R. part 314 (for drugs) and part 600 (for biological products) require recordkeeping for ten years); see also id. at 92626 (adding 21 C.F.R. §§ 4.104(b), 4.105(b)).

Readers are encouraged to refer to the Final Rule and the Code of Federal Regulations and to seek legal counsel as appropriate to determine how the new regulations might affect them. The FDA also indicates that it will publish guidance with further information on complying with the rule. Id. at 92609, 92612, 92617-19.

Originally printed in FDA Flash! Blog on February 2, 2017.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

15 Nov 2017, Conference, London, UK

Finnegan partner Leythem Wall will consider European claim drafting strategy and will lead the Chemical Workshop during a two-day course, hosted by Management Forum.

15 Nov 2017, Seminar, Amsterdam, Netherlands

Finnegan partner Anthony Tridico will lead Forum Institute for Management’s course comparing patent law in the United States and Europe.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.